keyword
MENU ▼
Read by QxMD icon Read
search

Tumor antigen

keyword
https://www.readbyqxmd.com/read/29050327/prognostic-and-predictive-value-of-serum-carcinoembryonic-antigen-levels-in-advanced-non-small-cell-lung-cancer-patients-with-epidermal-growth-factor-receptor-sensitive-mutations-and-receiving-tyrosine-kinase-inhibitors
#1
Xin Min Zhao, Jing Zhao, Kai Lin Xing, Si Sun, Zhi Guo Luo, Hui Jie Wang, Jia Lei Wang, Jian Hua Chang, Xiang Hua Wu
BACKGROUND: Despite the widespread use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in advanced or recurrent non-small cell lung cancer (NSCLC), no biomarkers for predicting the efficacy of EGFR-TKIs in patients with EGFR-sensitive mutations have yet been identified. The purpose of our study was to explore the effect of baseline serum tumor markers in stage IIIB/IV NSCLC patients treated with EGFR-TKIs. METHODS: One hundred and seventy-seven patients with stage IIIB/IV NSCLC who harbored EGFR-sensitive mutations and were treated with EGFR-TKIs were retrospectively reviewed...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29050282/effective-antitumor-peptide-vaccines-can-induce-severe-autoimmune-pathology
#2
Hussein Sultan, Jimena Trillo-Tinoco, Paulo Rodriguez, Esteban Celis
Immunotherapy has shown a tremendous success in treating cancer. Unfortunately, this success is frequently associated with severe autoimmune pathology. In this study, we used the transgenic RIP-gp mouse model to assess the antitumor therapeutic benefit of peptide vaccination while evaluating the possible associated autoimmune pathology. We report that palmitoylated gp33-41 peptide and poly-IC adjuvant vaccine (BiVax) generated ∼ 5-10 % of antigen specific T cell responses in wild type and supposedly immune tolerant RIP-gp mice...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29050178/-detection-and-clinical-significance-of-circulating-tumor-cells-in-patients-with-colorectal-carcinoma
#3
D Wang, Y C Yang, H W Yao, L Jin, J Wang, Z G Bai, Z T Zhang
Objective: To detect circulating tumor cells (CTC) in patients with colorectal carcinoma and to evaluate the relationship among CTC, clinic-pathological characteristics and prognosis of colorectal carcinoma. Methods: Peripheral blood samples were obtained from 109 patients with colorectal carcinoma in Department of General Surgery, Beijing Friendship Hospital, Capital Medical University from April 2014 to October 2016. There were 60 male and 49 female patients, aging from 33 to 86 years with a mean age of (65±10) years...
October 1, 2017: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/29050075/-specific-cytotoxicity-of-a-novel-her2-based-chimeric-antigen-receptor-modified-t-lymphocytes-against-her2-positive-tumor-cells
#4
H J Tang, Y Q Liu, X C Bian, H L Feng, B Gu, H Sun, C X Zuo, F Y Zhou, J Liu
Objective: To construct the third generation chimeric antigen receptor based on a novel humanized anti-HER2 H1-2 scFv, and to investigate the specific cytotoxicity of H1-2 CAR modified T lymphocytes(CAR-T) against HER2(+) tumor cells. Method: The expression cassette of the third generation CAR gene and anti-HER2 H1-2 scFv were constructed and cloned into lentivirus transfer plasmid, and then the third generation H1-2 CAR was transduced into human T lymphocytes using lentivirus.Enzyme linked immunosorbent assay was used to detect the expression of cytokines IL2, and LDH release assay was used to detect the cytotoxic effect of the H1-2 CAR-T...
October 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29050071/-poorly-differentiated-chordoma-with-ini1-loss-a-clinicopathologic-study
#5
J Y Feng, L Chen, Y Y Ma, H W Yang, L Chen
Objective: To analyze the clinicopathologic characteristics of poorly-differentiated chordoma with INI1 loss in children and to discuss the differential diagnosis. Methods: The clinical, radiological, histopathological profiles and molecular pathologic characteristics of two pediatric poorly differentiated chordoma cases with INI1 loss were reviewed. Results: The patients were a girl and a boy. Both lesions involved the slope. Both patients were presented with progressive muscle weakness or neck pain. Radiological examination showed clivus bone destruction and compression of the brain stem and cervical spinal cord...
October 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29049328/ca-19-9-and-ca-125-as-potential-predictors-of-disease-recurrence-in-resectable-lung-adenocarcinoma
#6
Sofi Isaksson, Per Jönsson, Nastaran Monsef, Hans Brunnström, Pär-Ola Bendahl, Mats Jönsson, Johan Staaf, Maria Planck
OBJECTIVES: Among patients who underwent primary surgery for non-small cell lung cancer (NSCLC), recurrent disease is frequent and cannot be accurately predicted solely from TNM stage and histopathological features. The aim of this study was to examine the association of tumor markers in pre-operative serum with recurrent disease. MATERIAL AND METHODS: Blood samples were collected prior to lung cancer surgery from 107 patients with stage I-III lung adenocarcinoma surgically treated at Lund University hospital, Lund, Sweden, between 2005 and 2011...
2017: PloS One
https://www.readbyqxmd.com/read/29048978/antitumor-effect-of-oral-cancer-vaccine-with-bifidobacterium-delivering-wt1-protein-to-gut-immune-system-is-superior-to-wt1-peptide-vaccine
#7
Toshiro Shirakawa, Koichi Kitagawa
Despite the revolutionary progress of immune checkpoint inhibitors (CPIs) for cancer immunotherapy, CPIs are effective only in a subset of patients. Combining CPIs and cancer vaccines to achieve better clinical outcomes is a reasonable approach since CPI enhances cancer vaccine-induced tumor-associated antigen (TAA) specific CTL. Among the various TAAs so far identified, WT1 protein is one of the most promising TAAs as a cancer vaccine target. Until now clinical trials of WT1 vaccine have demonstrated only modest clinical efficacy...
October 19, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29048935/chimeric-antigen-receptor-t-cell-therapy-for-solid-tumors-require-new-clinical-regimens
#8
Jinjing Xu, Kang Tian, Haixu Zhang, Liantao Li, Hongyan Liu, Jingjie Liu, Qing Zhang, Junnian Zheng
Chimeric antigen receptor modified T cell (CAR-T) therapy has achieved encouraging breakthroughs in the treatment of hematological malignancies. Nevertheless, this success has not yet been extrapolated to solid tumors. This review focuses on new clinical regimens that could improve the therapeutic efficacy of CAR-T in solid tumors. Areas covered: Herein, the authors reviewed recent clinical trials using CAR-T therapies for the treatment of solid tumors. Specifically, this review covered the following areas: (1) the current status of CAR-T cells in the treatment of solid tumors; (2) the major factors constraining the efficacy of CAR-T cells in solid tumors; and (3) opinions regarding the future of CAR-T as a treatment for solid tumors...
October 19, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29048671/adoptive-immunotherapy-combined-with-fp-treatment-for-head-and-neck-cancer-an-in%C3%A2-vitro-study
#9
Mayako Nishio-Nagai, Susumu Suzuki, Kazuhiro Yoshikawa, Ryuzo Ueda, Yoshiaki Kazaoka
FP treatment, which combines 5-fluorouracil (5-FU) and cisplatin (CDDP) chemotherapy, is widely used for treatment of advanced head and neck cancer (HNC). It has been suggested that these drugs cause immunomodulation in the cancer microenvironment, for example, downregulation of immunosuppressive cells such as regulatory T-cells (Tregs) and myeloid-derived suppressive cells (MDSCs), activating dendritic cells (DCs), and upregulation of tumor antigens and major histocompatibility complex (MHC) molecules in cancer cells leads to enhancement of cancer immunity, which is important in cancer treatment, as well as providing a direct killing effect...
October 2, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29046826/incorporation-of-functional-elements-enhances-the-antitumor-capacity-of-car-t-cells
#10
REVIEW
Le Qin, Ruocong Zhao, Peng Li
As chimeric antigen receptor (CAR) T cells have displayed an unprecedented efficacy in the treatment of CD19-positive malignances, it is believed that this cell therapy will be a milestone in the history of mankind's conquering of cancer. However, there are some issues that restrict CAR T cells from reaching their optimal anti-tumor capacity, especially in the treatment of solid tumors. Inhibitory cytokines, immune checkpoint molecules, hypoxia and other adverse factors have been reported to be involved in this process...
2017: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29046795/comparison-of-clinicopathological-characteristics-between-cirrhotic-and-non-cirrhotic-patients-with-intrahepatic-cholangiocarcinoma-a-large-scale-retrospective-study
#11
Lei Yuan, Xianwu Luo, Xinyuan Lu, Bin Yi, Kaijian Chu, Quanyu Cai, Xiaoqing Jiang
The effect of cirrhosis on the characteristics of intrahepatic cholangiocarcinoma (ICC) has not been fully elucidated. The purpose of this study was to investigate how cirrhosis affects the clinicopathological characteristics and survival of surgically treated ICC patients. A total of 1,312 ICC patients surgically treated between January 2007 and December 2011 at a single institution were retrospectively reviewed and the clinicopathological data were compared between cirrhotic and non-cirrhotic patients. Univariate and multivariate analyses were performed to identify significant and independent prognostic factors in this cohort...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29046789/a-retrospective-study-of-late-adverse-events-in-proton-beam-therapy-for-prostate-cancer
#12
Hirokazu Makishima, Hitoshi Ishikawa, Keiichi Tanaka, Yutaro Mori, Masashi Mizumoto, Kayoko Ohnishi, Teruhito Aihara, Nobuyoshi Fukumitsu, Toshiyuki Okumura, Hideyuki Sakurai
The efficacy and safety of proton beam therapy (PBT) were retrospectively evaluated in 111 consecutive patients with prostate cancer who underwent definitive PBT between 2008 and 2012. Following exclusion of 18 patients due to treatment suspension, loss to follow-up, and histology, the analysis included 93 patients with a median age of 68 years (range, 49-81 years). A total of 7, 32 and 54 prostate cancer patients were classified as low-, intermediate- and high-risk, respectively, as follows: High-risk, T≥3a or prostate-specific antigen (PSA) ≥20 ng/ml or Gleason Score ≥8; low-risk, T ≤2b and PSA≤10 ng/ml and Gleason Score=6; intermediate-risk, all other combinations...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29046337/cathepsin-b-is-dispensable-for-cellular-processing-of-cathepsin-b-cleavable-antibody-drug-conjugates
#13
Niña G Caculitan, Josefa Dela Cruz Chuh, Yong Ma, Donglu Zhang, Katherine R Kozak, Yichin Liu, Thomas H Pillow, Jack Sadowsky, Tommy K Cheung, Qui Phung, Benjamin Haley, Byoung-Chul Lee, Robert Akita, Mark X Sliwkowski, Andrew G Polson
Antibody-drug conjugates (ADCs) are designed to selectively bind to tumor antigens via the antibody and release their cytotoxic payload upon internalization. Controllable payload release through judicious design of the linker has been an early technological milestone. Here, we examine the effect of the protease-cleavable valine-citrulline (VC(S)) linker on ADC efficacy. The VC(S) linker was designed to be cleaved by cathepsin B, a lysosomal cysteine protease. Surprisingly, suppression of cathepsin B expression via CRISPR-Cas9 gene deletion or shRNA knockdown had no effect on the efficacy of ADCs with VC(S) linkers armed with a monomethyl auristatin E (MMAE) payload...
October 18, 2017: Cancer Research
https://www.readbyqxmd.com/read/29046141/generation-and-characterization-of-a-bispecific-antibody-targeting-both-pd-1-and-c-met
#14
Yi Wu, Min Yu, Zujun Sun, Weihua Hou, Yuxiong Wang, Qingyun Yuan, Wei Mo
Bispecific antibodies, BsAbs, are molecules with the ability to bind to two different epitopes on the same or different antigens. The goal of this study was to create a novel bispecific antibody targeting both cellular-mesenchymal to epithelial transition factor(c-MET) and programmed death-1(PD-1) as an anti-cancer therapeutic candidate. Upon binding to the c-MET antigen on a tumor cell and the PD-1 antigen on a T cell, a BsAb can redirect T cells for tumor killing. Based on the original sequences of PD-1 and c-MET mAbs, a BsAb gene was designed, and cloned into the pCEP4 vector...
October 17, 2017: Protein and Peptide Letters
https://www.readbyqxmd.com/read/29045781/development-of-clickable-monophosphoryl-lipid-as-towards-semi-synthetic-conjugates-with-tumor-associated-carbohydrate-antigens
#15
Marcello Ziaco, Sabina Górska, Serena Traboni, Agnieszka Maria Razim, Angela Casillo, Alfonso Iadonisi, Andrzej Gamian, Maria Michela Corsaro, Emiliano Bedini
A semi-synthetic strategy for the obtainment of monophosphoryl lipid A derivatives equipped with clickable (azide, alkyne, double bond, a thiol precursor) moieties, starting from the native lipid A isolated from Escherichia coli, is here presented. These lipid A derivatives can be conjugated with other interesting biomolecules, such as tumor-associated carbohydrate antigens (TACAs). In this way, the immunostimulant activity of monophosphoryl lipid A can significantly improve the immunogenicity of TACAs, thus opening an access to potential self-adjuvant anticancer vaccine candidates...
October 18, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29045711/the-endothelial-prostate-specific-membrane-antigen-is-highly-expressed-in-gliosarcoma-and-visualized-by-68ga-psma-11-pet-a-theranostic-outlook-for-brain-tumor-patients
#16
Marcus Unterrainer, Maximilian Niyazi, Viktoria Ruf, Peter Bartenstein, Nathalie L Albert
No abstract text is available yet for this article.
October 17, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29045511/mechanisms-regulating-t-cell-infiltration-and-activity-in-solid-tumors
#17
E Lanitis, D Dangaj, M Irving, G Coukos
T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in resected tumor samples derived from long-surviving patients, and impressive clinical responses to various immunotherapies that reinvigorate them. Indeed, tumors can upregulate a wide array of defense mechanisms, both direct and indirect, to suppress the ability of Tcells to reach the tumor bed and mount curative responses upon infiltration. In addition, patient and tumor genetics, previous antigenic experience, and the microbiome, are all important factors in shaping the T-cell repertoire and sensitivity to immunotherapy...
September 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29043661/development-of-adenosine-deaminase-specific-igy-antibodies-diagnostic-and-inhibitory-application
#18
Agnieszka Łupicka-Słowik, Mateusz Psurski, Renata Grzywa, Kamila Bobrek, Patrycja Smok, Maciej Walczak, Andrzej Gaweł, Tadeusz Stefaniak, Józef Oleksyszyn, Marcin Sieńczyk
Adenosine deaminase (ADA) is currently used as a diagnostic marker for tuberculous pleuritis. Although ADA has been suggested as a potential marker for several types of cancer, the importance of each of ADA isoforms as well as their levels and enzymatic activities in tumors need to be further investigated. Herein we developed avian immunoglobulin Y highly specific to human ADA via hens immunization with calf adenosine deaminase. The obtained antibodies were used for the development of a sensitive double-egg yolk immunoglobulin (IgY) sandwich ELISA assay with an ADA detection limit of 0...
October 17, 2017: Applied Biochemistry and Biotechnology
https://www.readbyqxmd.com/read/29043453/serum-carbohydrate-antigen-125-is-a-significant-prognostic-marker-in-patients-with-unresectable-advanced-or-recurrent-gastric-cancer
#19
Tsutomu Namikawa, Yasuhiro Kawanishi, Kazune Fujisawa, Eri Munekage, Jun Iwabu, Masaya Munekage, Hiromichi Maeda, Hiroyuki Kitagawa, Michiya Kobayashi, Kazuhiro Hanazaki
PURPOSE: We evaluated the diagnostic and prognostic value of three tumor markers: carcino-embryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 125 (CA125), in the pretreatment serum of patients with unresectable advanced or recurrent gastric cancer. METHODS: The subjects of this retrospective analysis were 245 patients with unresectable advanced or recurrent gastric cancer diagnosed at Kochi Medical School between 2007 and 2015. We ascertained the sensitivity of CEA, CA19-9, and CA125 to identify a certain survival time and then evaluated the relative prognosis of the patients...
October 17, 2017: Surgery Today
https://www.readbyqxmd.com/read/29042925/calreticulin-is-an-effective-immunologic-adjuvant-to-tumor-associated-antigens
#20
Jun Wang, Zhi Peng Gao, Song Qin, Chang Bai Liu, Li Li Zou
As a key molecule involved in cell recognition, calreticulin (CRT) may be expressed on the surface of (pre-) apoptotic cells and provide the signal that is recognized by dendritic cells (DCs) or other antigen presenting cells (APCs), which results in phagocytosis. Within the APCs, tumor-associated antigens (TAAs) may be subsequently presented to T lymphocytes, which triggers a specific antitumor immune response. It has been hypothesized that CRT is able to act as the immunologic adjuvant and translocate itself and TAAs to the cell surface and induce a specific antitumor immune response...
October 2017: Experimental and Therapeutic Medicine
keyword
keyword
119623
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"